Space Mission Launched Neurodegeneration Study
The National Stem Cell Foundation has sent a new neurodegeneration research experiment to the International Space Station.
Updated on Oct. 14, 2026 in Alzheimer’s
Live Poll
Do you believe space-based research provides enough medical value to justify the high costs?
The National Stem Cell Foundation, in collaboration with Axiom Space and the Saudi Space Agency, has launched a study to the International Space Station aboard the SpaceX CRS-35 mission. This research examines three neurological conditions, including Alzheimer’s disease, Parkinson’s disease, and Primary Progressive Multiple Sclerosis.
Why it matters
Researchers are investigating whether genetic ancestry and population-specific factors influence how disease therapies perform. By utilizing the microgravity environment, scientists aim to observe molecular changes in brain organoids that develop too slowly for traditional lab analysis.
The study focuses on three neurodegenerative conditions, specifically Parkinson's, Primary Progressive Multiple Sclerosis, and Alzheimer's disease. Researchers previously found that brain organoids reach maturity more rapidly in space than in Earth-based laboratories.
The players
National Stem Cell Foundation
This organization facilitates the advancement of stem cell research to develop new treatments for chronic diseases.
Axiom Space
This company provides infrastructure and mission support for research conducted in low Earth orbit.
Saudi Space Agency
This government entity oversees national aerospace programs and international research partnerships.
King Abdullah University of Science and Technology
This institution focuses on global research initiatives and graduate-level education in science and technology.
The details
The mission features cell lines from diverse patient populations, including samples from Saudi Arabia and the United Kingdom, specifically incorporating early-onset Alzheimer's mutations. Experts from the King Abdullah University of Science and Technology assisted in preparing the research materials to help refine drug development and screening applications.
Timeline
The collaboration and mission launch were announced on October 14, 2026.
Health Landscape
This project extends the International Space Station's orbital research program by testing how genetic ancestry influences cellular responses to therapies in microgravity. It signals a move toward using space-based environments to accelerate drug development for complex neurological disorders.
This research could eventually lead to more personalized treatment options by identifying how genetic backgrounds affect drug responses. While the study is in its early stages, it offers a potential path toward accelerated drug screening for those affected by neurodegenerative conditions.
The takeaway
Advancing medical research in microgravity helps scientists identify disease pathways that are otherwise difficult to study on Earth. These insights aim to improve the efficacy of future treatments for patients living with neurodegenerative illnesses.
Further reading
Find more context on current medical breakthroughs in the Alzheimer’s section.
Live Poll
Do you believe space-based research provides enough medical value to justify the high costs?
